WT1 and pancreatic ductal adenocarcinoma: The chemoimmunotherapy regimen, including WT1-DC vaccine, potently activates WT1-specific immunity in unresectable advanced pancreatic ductal adenocarcinoma patients, potentially remodeling the tumor microenvironment to facilitate conversion surgery and improve clinical outcomes.